JP5845170B2 - 組換えｆｓｈを精製する方法 - Google Patents
組換えｆｓｈを精製する方法 Download PDFInfo
- Publication number
- JP5845170B2 JP5845170B2 JP2012502514A JP2012502514A JP5845170B2 JP 5845170 B2 JP5845170 B2 JP 5845170B2 JP 2012502514 A JP2012502514 A JP 2012502514A JP 2012502514 A JP2012502514 A JP 2012502514A JP 5845170 B2 JP5845170 B2 JP 5845170B2
- Authority
- JP
- Japan
- Prior art keywords
- chromatography
- fsh
- anion exchange
- exchange chromatography
- resin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 111
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims description 162
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims description 162
- 229940028334 follicle stimulating hormone Drugs 0.000 claims description 161
- 238000005571 anion exchange chromatography Methods 0.000 claims description 56
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims description 51
- 239000012528 membrane Substances 0.000 claims description 45
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 claims description 43
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 claims description 43
- 239000011347 resin Substances 0.000 claims description 43
- 229920005989 resin Polymers 0.000 claims description 43
- 238000001042 affinity chromatography Methods 0.000 claims description 35
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 30
- 238000000108 ultra-filtration Methods 0.000 claims description 27
- 230000008569 process Effects 0.000 claims description 26
- 238000005277 cation exchange chromatography Methods 0.000 claims description 25
- 150000007523 nucleic acids Chemical class 0.000 claims description 22
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 22
- 229920002684 Sepharose Polymers 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 238000000746 purification Methods 0.000 claims description 16
- 239000012609 strong anion exchange resin Substances 0.000 claims description 15
- 239000003446 ligand Substances 0.000 claims description 14
- 229920000936 Agarose Polymers 0.000 claims description 13
- 150000001768 cations Chemical class 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- 239000011159 matrix material Substances 0.000 claims description 12
- 238000004587 chromatography analysis Methods 0.000 claims description 11
- 125000000524 functional group Chemical group 0.000 claims description 11
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims description 11
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 10
- 238000001728 nano-filtration Methods 0.000 claims description 9
- 238000004271 weak anion exchange chromatography Methods 0.000 claims description 9
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 8
- 238000005341 cation exchange Methods 0.000 claims description 7
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000011324 bead Substances 0.000 claims description 5
- 150000002500 ions Chemical class 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 229910021645 metal ion Inorganic materials 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 239000012475 sodium chloride buffer Substances 0.000 claims description 3
- GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 claims description 2
- JQYMGXZJTCOARG-UHFFFAOYSA-N Reactive blue 2 Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC(S(O)(=O)=O)=C1 JQYMGXZJTCOARG-UHFFFAOYSA-N 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 239000003480 eluent Substances 0.000 claims 2
- 239000012619 Butyl Sepharose® Substances 0.000 claims 1
- 239000012541 Fractogel® Substances 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 38
- 239000000872 buffer Substances 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 description 20
- 239000011780 sodium chloride Substances 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 230000004071 biological effect Effects 0.000 description 11
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 238000011210 chromatographic step Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000007983 Tris buffer Substances 0.000 description 8
- 239000003463 adsorbent Substances 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- 239000004695 Polyether sulfone Substances 0.000 description 7
- 239000003957 anion exchange resin Substances 0.000 description 7
- 239000001913 cellulose Substances 0.000 description 7
- 229920002678 cellulose Polymers 0.000 description 7
- 230000013595 glycosylation Effects 0.000 description 7
- 238000006206 glycosylation reaction Methods 0.000 description 7
- 229920006393 polyether sulfone Polymers 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000012505 Superdex™ Substances 0.000 description 6
- 150000001450 anions Chemical class 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000013017 sartobind Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000003729 cation exchange resin Substances 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000012504 chromatography matrix Substances 0.000 description 5
- YKCWQPZFAFZLBI-UHFFFAOYSA-N cibacron blue Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC=C1S(O)(=O)=O YKCWQPZFAFZLBI-UHFFFAOYSA-N 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 239000004627 regenerated cellulose Substances 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 4
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 4
- 238000011026 diafiltration Methods 0.000 description 4
- -1 dimethylaminoethyl Chemical group 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 238000003306 harvesting Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108700010070 Codon Usage Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000006771 Gonadotropins Human genes 0.000 description 3
- 108010086677 Gonadotropins Proteins 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 101000893054 Homo sapiens Follitropin subunit beta Proteins 0.000 description 3
- 108010073521 Luteinizing Hormone Proteins 0.000 description 3
- 102000009151 Luteinizing Hormone Human genes 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 229940023913 cation exchange resins Drugs 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- 102000034238 globular proteins Human genes 0.000 description 3
- 108091005896 globular proteins Proteins 0.000 description 3
- 239000002622 gonadotropin Substances 0.000 description 3
- 229960000789 guanidine hydrochloride Drugs 0.000 description 3
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 3
- 230000005661 hydrophobic surface Effects 0.000 description 3
- 208000021267 infertility disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 229940040129 luteinizing hormone Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000002305 strong-anion-exchange chromatography Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 101800005309 Carboxy-terminal peptide Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 2
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 2
- 239000007994 TES buffer Substances 0.000 description 2
- 239000007997 Tricine buffer Substances 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000007998 bicine buffer Substances 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 239000006167 equilibration buffer Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 108010081934 follitropin beta Proteins 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000021595 spermatogenesis Effects 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000012610 weak anion exchange resin Substances 0.000 description 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 101001038874 Homo sapiens Glycoprotein hormones alpha chain Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
- 206010033157 Ovarian enlargement Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042573 Superovulation Diseases 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 239000003011 anion exchange membrane Substances 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 150000001508 asparagines Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000000366 colloid method Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- QKSIFUGZHOUETI-UHFFFAOYSA-N copper;azane Chemical compound N.N.N.N.[Cu+2] QKSIFUGZHOUETI-UHFFFAOYSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 229940057854 gonal f Drugs 0.000 description 1
- 108010021083 hen egg lysozyme Proteins 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 201000003368 hypogonadotropic hypogonadism Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000003751 purification from natural source Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 230000000920 spermatogeneic effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000012799 strong cation exchange Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000013060 ultrafiltration and diafiltration Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09157133 | 2009-04-01 | ||
| EP09157133.1 | 2009-04-01 | ||
| PCT/EP2010/002111 WO2010115586A2 (en) | 2009-04-01 | 2010-04-01 | Method for purifying recombinant fsh |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015177674A Division JP6231056B2 (ja) | 2009-04-01 | 2015-09-09 | 組換えｆｓｈを精製する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012522736A JP2012522736A (ja) | 2012-09-27 |
| JP2012522736A5 JP2012522736A5 (https=) | 2013-05-09 |
| JP5845170B2 true JP5845170B2 (ja) | 2016-01-20 |
Family
ID=42153744
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012502514A Expired - Fee Related JP5845170B2 (ja) | 2009-04-01 | 2010-04-01 | 組換えｆｓｈを精製する方法 |
| JP2015177674A Expired - Fee Related JP6231056B2 (ja) | 2009-04-01 | 2015-09-09 | 組換えｆｓｈを精製する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015177674A Expired - Fee Related JP6231056B2 (ja) | 2009-04-01 | 2015-09-09 | 組換えｆｓｈを精製する方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US9096683B2 (https=) |
| EP (1) | EP2414380B1 (https=) |
| JP (2) | JP5845170B2 (https=) |
| KR (1) | KR101761168B1 (https=) |
| CN (1) | CN102448979B (https=) |
| AU (1) | AU2010234028B2 (https=) |
| BR (1) | BRPI1012647B1 (https=) |
| CA (1) | CA2755927A1 (https=) |
| CY (1) | CY1116963T1 (https=) |
| DK (1) | DK2414380T3 (https=) |
| EA (1) | EA028065B1 (https=) |
| ES (1) | ES2552055T3 (https=) |
| HR (1) | HRP20151086T1 (https=) |
| HU (1) | HUE025959T2 (https=) |
| IL (1) | IL215234A (https=) |
| ME (1) | ME02277B (https=) |
| MX (1) | MX2011010480A (https=) |
| NZ (1) | NZ595661A (https=) |
| PL (1) | PL2414380T3 (https=) |
| PT (1) | PT2414380E (https=) |
| RS (1) | RS54318B1 (https=) |
| SI (1) | SI2414380T1 (https=) |
| SM (1) | SMT201500276B (https=) |
| UA (1) | UA106369C2 (https=) |
| WO (1) | WO2010115586A2 (https=) |
| ZA (1) | ZA201106800B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016027050A (ja) * | 2009-04-01 | 2016-02-18 | ラティオファーム ゲーエムベーハー | 組換えｆｓｈを精製する方法 |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103570820B (zh) * | 2012-08-06 | 2015-11-18 | 齐鲁制药有限公司 | 一种重组人促卵泡激素的纯化方法 |
| KR101516054B1 (ko) * | 2012-11-21 | 2015-05-06 | 씨제이헬스케어 주식회사 | 신규한 지속형 인간 성장호르몬 단량체를 제조하는 방법 |
| CN103059125B (zh) * | 2012-12-27 | 2015-08-12 | 浙江海正药业股份有限公司 | 重组人促卵泡激素的纯化方法 |
| EP2968391A1 (en) | 2013-03-13 | 2016-01-20 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| CN103539860B (zh) * | 2013-11-01 | 2014-12-03 | 广州优联康医药科技有限公司 | 一种长效重组人促卵泡激素融合蛋白 |
| CN103539861B (zh) * | 2013-11-01 | 2015-02-18 | 广州联康生物科技有限公司 | 长效重组人促卵泡激素融合蛋白 |
| KR20160131113A (ko) * | 2014-04-18 | 2016-11-15 | 카딜라 핼쓰캐어 리미티드 | 고나도트로핀의 신규한 정제 방법 |
| CN104479005B (zh) * | 2014-09-05 | 2017-10-31 | 上海丽珠制药有限公司 | 一种促性腺激素纯化的方法 |
| CN105461799A (zh) * | 2015-12-31 | 2016-04-06 | 哈药集团技术中心 | 一种重组人促卵泡生成素的纯化方法 |
| CN106117342B (zh) * | 2016-07-07 | 2020-01-03 | 江西浩然生物医药有限公司 | 一种高纯度尿促卵泡素的制备方法 |
| RU2694598C1 (ru) * | 2018-08-07 | 2019-07-16 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Клеточная линия huFSHKKc6 - продуцент рекомбинантного человеческого фолликулостимулирующего гормона (ФСГ) и способ получения ФСГ с использованием данной линии |
| CN114867741A (zh) * | 2019-12-26 | 2022-08-05 | 株式会社Lg化学 | 纯化促卵泡激素的方法 |
| KR102283871B1 (ko) * | 2021-03-02 | 2021-08-02 | 한국원자력연구원 | 크로마토그래피를 이용한 무담체 홀뮴-166의 분리 방법, 분리 장치 및 이에 의하여 분리된 무담체 홀뮴-166 |
| CN113372433B (zh) * | 2021-03-12 | 2022-10-11 | 上海景泽生物技术有限公司 | 纯化fsh方法 |
| CN114591414A (zh) * | 2022-03-24 | 2022-06-07 | 江西浩然生物制药有限公司 | 一种人绒毛膜促性腺激素的制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4923805A (en) | 1983-11-02 | 1990-05-08 | Integrated Genetics, Inc. | Fsh |
| US4840896A (en) | 1983-11-02 | 1989-06-20 | Integrated Genetics, Inc. | Heteropolymeric protein |
| US6455282B1 (en) * | 1983-11-02 | 2002-09-24 | Genzyme Corporation | Cells, vectors and methods for producing biologically active TSH |
| IT1206302B (it) | 1987-06-26 | 1989-04-14 | Serono Cesare Ist Ricerca | Ormone follicolo-stimolante urinario |
| CA2018676C (en) | 1989-06-20 | 2003-05-06 | Christie A. Kelton | Novel heteropolymeric protein production methods |
| US5021160A (en) * | 1990-01-09 | 1991-06-04 | Gelman Sciences, Inc. | Strongly acidic microporous membranes for cation exchange |
| DE4440587A1 (de) | 1994-11-14 | 1996-05-15 | Fliether Karl Gmbh & Co | Basquill-Schloß |
| US6261823B1 (en) * | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
| ES2332931T3 (es) | 1997-06-25 | 2010-02-15 | Merck Serono Sa | Analogos de hormonas glicoproteinicas entrelazadas por disulfuro, su preparacion y uso. |
| US5990288A (en) * | 1997-10-21 | 1999-11-23 | Vitro Diagnostics, Inc. | Method for purifying FSH |
| US6414123B1 (en) * | 1997-10-21 | 2002-07-02 | Vitro Diagnostics, Inc. | Method for purifying FSH |
| BRPI0010677B8 (pt) * | 1999-04-16 | 2021-05-25 | Inst Massone S A | processo de purificação de gonadotropinas urinárias humanas a partir de gonadotropinas brutas. |
| WO2001058493A1 (en) | 2000-02-11 | 2001-08-16 | Maxygen Aps | Conjugates of follicle stimulating hormones |
| US7157277B2 (en) * | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| CA2483650A1 (en) | 2002-05-31 | 2003-12-11 | E.I. Du Pont De Nemours And Company | Copolymers having tunable energy levels and color of emission |
| DK1610822T4 (en) | 2003-04-02 | 2019-01-14 | Ares Trading Sa | Liquid pharmaceutical FSH and LH formulations together with a nonionic surfactant |
| EP1697412B1 (en) * | 2003-12-22 | 2009-10-21 | Ares Trading S.A. | Method for purifying fsh |
| DE602005009856D1 (de) * | 2004-11-09 | 2008-10-30 | Ares Trading Sa | Verfahren zur reinigung von fsh |
| ES2572629T3 (es) * | 2005-12-09 | 2016-06-01 | Ares Trading S.A. | Método para purificar FSH o un mutante de FSH |
| EP1960419B1 (en) | 2005-12-09 | 2016-03-16 | Ares Trading S.A. | Method for purifying fsh or a fsh mutant |
| DK2170942T3 (da) * | 2007-06-28 | 2013-11-04 | Biogenerix Ag | Fsh-producerende celleklon |
| AR067536A1 (es) * | 2007-07-17 | 2009-10-14 | Hoffmann La Roche | Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea |
| JP5845170B2 (ja) * | 2009-04-01 | 2016-01-20 | ラティオファーム ゲーエムベーハー | 組換えｆｓｈを精製する方法 |
-
2010
- 2010-04-01 JP JP2012502514A patent/JP5845170B2/ja not_active Expired - Fee Related
- 2010-04-01 RS RS20150682A patent/RS54318B1/sr unknown
- 2010-04-01 AU AU2010234028A patent/AU2010234028B2/en not_active Ceased
- 2010-04-01 ME MEP-2015-172A patent/ME02277B/me unknown
- 2010-04-01 CN CN201080022681.1A patent/CN102448979B/zh active Active
- 2010-04-01 US US13/262,622 patent/US9096683B2/en not_active Expired - Fee Related
- 2010-04-01 BR BRPI1012647-3A patent/BRPI1012647B1/pt not_active IP Right Cessation
- 2010-04-01 ES ES10713424.9T patent/ES2552055T3/es active Active
- 2010-04-01 KR KR1020117025974A patent/KR101761168B1/ko not_active Expired - Fee Related
- 2010-04-01 EP EP10713424.9A patent/EP2414380B1/en active Active
- 2010-04-01 DK DK10713424.9T patent/DK2414380T3/en active
- 2010-04-01 HU HUE10713424A patent/HUE025959T2/en unknown
- 2010-04-01 PT PT107134249T patent/PT2414380E/pt unknown
- 2010-04-01 NZ NZ595661A patent/NZ595661A/xx not_active IP Right Cessation
- 2010-04-01 UA UAA201112796A patent/UA106369C2/ru unknown
- 2010-04-01 PL PL10713424T patent/PL2414380T3/pl unknown
- 2010-04-01 EA EA201171199A patent/EA028065B1/ru not_active IP Right Cessation
- 2010-04-01 MX MX2011010480A patent/MX2011010480A/es unknown
- 2010-04-01 SI SI201031050T patent/SI2414380T1/sl unknown
- 2010-04-01 HR HRP20151086TT patent/HRP20151086T1/hr unknown
- 2010-04-01 WO PCT/EP2010/002111 patent/WO2010115586A2/en not_active Ceased
- 2010-04-01 CA CA2755927A patent/CA2755927A1/en not_active Abandoned
-
2011
- 2011-09-15 ZA ZA2011/06800A patent/ZA201106800B/en unknown
- 2011-09-19 IL IL215234A patent/IL215234A/en active IP Right Grant
-
2015
- 2015-06-15 US US14/739,935 patent/US20150353599A1/en not_active Abandoned
- 2015-09-09 JP JP2015177674A patent/JP6231056B2/ja not_active Expired - Fee Related
- 2015-10-30 CY CY20151100971T patent/CY1116963T1/el unknown
- 2015-11-04 SM SM201500276T patent/SMT201500276B/it unknown
-
2016
- 2016-07-01 US US15/200,714 patent/US20160304575A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016027050A (ja) * | 2009-04-01 | 2016-02-18 | ラティオファーム ゲーエムベーハー | 組換えｆｓｈを精製する方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6231056B2 (ja) | 組換えｆｓｈを精製する方法 | |
| EP2504350B1 (en) | Process for the purification of glycoproteins | |
| EP2119727B1 (en) | Method for production of recombinant human FSH | |
| CN101087805B (zh) | Fsh的纯化方法 | |
| CN1191545A (zh) | 高纯度白蛋白生产方法 | |
| KR20060135656A (ko) | Ｆｓｈ를 정제하는 방법 | |
| CN110563832B (zh) | 一种高纯度重组促卵泡刺激素纯化方法 | |
| JP4933439B2 (ja) | Ｆｓｈの精製方法 | |
| HK1108704B (en) | Method for purifying fsh |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130325 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130325 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20140311 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140812 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141112 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141119 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141210 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150512 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150909 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150917 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151027 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151120 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5845170 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |